NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Amir Heshmatpour as Chief Executive Officer, effective immediately, while Dr. Thomas Chen transitions to focus on his roles as Chief Medical Officer and Chief Scientific Officer [1][2][3] - Heshmatpour has a strong background in corporate strategy and business development, which is expected to drive NeOnc's lead candidates toward commercialization [3][4] - The company is advancing its NEO™ platform, which is protected by over 179 patents, and aims to transform care for patients with CNS cancers [4][6] Company Leadership Transition - Amir Heshmatpour, previously President, will now serve as CEO and continue as Executive Chairman [1][4] - Dr. Thomas Chen, the founder, will concentrate on clinical trials and scientific strategy, ensuring leadership in innovative developments [2][3] Strategic Achievements - Under Heshmatpour's leadership, NeOnc secured a $50 million strategic partnership with Quazar Investment and established a UAE-based subsidiary, NuroMENA [3] - The company has expanded its Scientific Advisory Board with renowned neuro-oncologists from Duke and NYU Langone Health [3] Product Development and Clinical Trials - NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [6] - The company focuses on overcoming the blood-brain barrier with its proprietary chemotherapy agents, which have shown positive effects in laboratory tests and clinical trials [6]